Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239447 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
- 11
- Study locations
NCT00239447: Completed Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
NCT00239447 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 131 participants, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (87% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00239447, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
- 11
- Study locations
Study Summary
Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
Conditions Studied
Interventions
- DRUG Tiotropium
- DEVICE HandiHaler
- DEVICE Respimat SMI
Study Locations (11)
California
- Boehringer Ingelheim Investigational Site - San Diego
- San Jose Clinical Research - San Jose
- Boehringer Ingelheim Investigational Site - Stockton
Arkansas
- Division of Pulmonary and Critical Care Medicine - Little Rock
Colorado
- National Jewish Medical and Research Center - Denver
Louisiana
- LSU MC-Sheveport - Shreveport
Minnesota
- Minisota Lung Center - Minneapolis
North Carolina
- Wake Forest University School of Medicine - Winston-Salem
South Carolina
- Spartanburg Medical Research - Spartanburg
Washington
- Boehringer Ingelheim Investigational Site - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2002-11-26 |
| Est. Completion | 2004-04-29 |
| Phase | Phase 3 |
What the finished NCT00239447 record still lists
NCT00239447 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, below the 1,042-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 3 interventions - of which Tiotropium is the first listed.
NCT00239447 lists 11 locations in 9 states (California, Arkansas, Colorado).
Frequently Asked Questions
What is clinical trial NCT00239447 about?
NCT00239447 is a clinical study titled "Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD". Non-inferiority of lung function response to Tiotropium inhalation solution compared to Spiriva HandiHaler
What is the current status of trial NCT00239447?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2002-11-26. Estimated completion is 2004-04-29.
What conditions does trial NCT00239447 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00239447?
The interventions under investigation include: Tiotropium (DRUG), HandiHaler (DEVICE), Respimat SMI (DEVICE).
Who is sponsoring clinical trial NCT00239447?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00239447 being conducted?
This trial has 11 study locations across Arkansas, California, Colorado, Louisiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00239447's enrollment target sits among peer trials
131 50th of 74 higher than 25 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI